Answers are grounded in this paper and cite their sources.
Objective KMT2A-rearranged B-cell acute lymphoblastic leukemia (B-ALL) involves diverse partner genes. KMT2A::FOXR1 has previously been described in neuroblastoma but not in hematologic malignancies. This study reports the first known case of KMT2A::FOXR1 in B-ALL.Case presentation A 39-year-old woman presented with fever and fatigue. Peripheral blood examination revealed abnormal blood counts and circulating blasts. Bone marrow morphology and flow cytometric immunophenotyping established the diagnosis of B-ALL. Conventional cytogenetic analysis showed no apparent 11q23 abnormality, whereas targeted RNA sequencing (RNA-seq) identified a KMT2A::FOXR1 fusion transcript. Subsequent KMT2A break-apart fluorescence in situ hybridization (FISH) demonstrated loss of the 3′ KMT2A probe signal, supporting an unbalanced KMT2A rearrangement. The patient was diagnosed with B-ALL harboring a KMT2A::FOXR1 rearrangement. Following induction with part A of the hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone regimen, the patient achieved complete remission with incomplete hematologic recovery and flow cytometric measurable residual disease negativity. At the time of writing, treatment was continuing as planned.Discussion and conclusions This case expands the spectrum of KMT2A partner genes in B-ALL and highlights the complementary diagnostic value of RNA-seq and FISH when conventional cytogenetic analysis is unrevealing. Further studies are required to clarify the biological and clinical significance of KMT2A::FOXR1.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: